GSK3335065 / GSK - LARVOL DELTA

Assessment of the safety, pharmacokinetics and pharmacodynamics of GSK3335065, an inhibitor of kynurenine monooxygenase, in a randomised placebo controlled First Time in Human study in healthy volunteers. (PubMed, Br J Clin Pharmacol) - "However, a broad complex ventricular tachycardia was observed in this subject which was judged to be a Serious Adverse Event and resulted in early termination of the study. While development of GSK3335065 was subsequently discontinued, significant confounding factors hinder a clear interpretation that the tachycardia was directly related to administration of the compound."

Clinical • Journal • PK/PD data • Cardiovascular • Pancreatitis • Ventricular Tachycardia